Loading...

GeoVax Labs, Inc.

GOVXW•NASDAQ
Healthcare
Biotechnology
$0.03
$0.00(0.40%)

GeoVax Labs, Inc. (GOVXW) Stock Overview

Explore GeoVax Labs, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 62.2/100

Key Financials

Market Cap10.4M
P/E Ratio-0.42
EPS (TTM)N/A
ROE-5.12%
Fundamental Analysis

AI Price Forecasts

1 Week$0.04
1 Month$0.12
3 Months$0.19
1 Year Target$0.03

GOVXW Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of GeoVax Labs, Inc. (GOVXW) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $0.03.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.42 and a market capitalization of 10.4M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for GOVXWStats details for GOVXW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for GOVXWAnalyst Recommendations details for GOVXW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is also developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; GEO-EM01 for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. GeoVax Labs, Inc. has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.

CEO

David Alan Dodd

Employees

17

Headquarters

1900 Lake Park Drive, Smyrna, DE

Founded

1970

Frequently Asked Questions

;